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Spinocerebellar ataxia 1 is an autosomal dominant disease characterized by
neurodegeneration and motor dysfunction. In disease pathogenesis, polyglutamine
expansion within Ataxin-1, a gene involved in transcriptional repression, causes protein
nuclear inclusions to form. Most notably, neuronal dysfunction presents in Purkinje cells.
However, the effect of mutant Ataxin-1 is not entirely understood. Two mouse models are
employed to represent spinocerebellar ataxia 1, a B05 transgenic model that specifically
expresses mutant Ataxin-1 in Purkinje cells, and a Sca1 154Q/2Q model that inserts the
polyglutamine expansion into the mouse Ataxin-1 locus so that the mutant Ataxin-1 is
expressed in all cells that express Ataxin-1. This review aims to summarize and evaluate
the wide variety of therapies proposed for spinocerebellar ataxia 1, specifically gene and
stem cell therapies.
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INTRODUCTION
Spinocerebellar ataxia (SCA) is a group of autosomal dominant neurodegenerative diseases
characterized by progressive degeneration in the spinal cord, brain stem, and cerebellum. SCA
types 1–36 have been identified, each attributable to a different gene. SCA genetic abnormalities
are most commonly caused by cytosine-adenosine-guanine (CAG) repeat expansion leading to a
polyglutamine expanded protein product presumed to be toxic to neurons (Whaley et al., 2011;
Table 1).
In spinocerebellar ataxia 1 (SCA 1), the accumulation of the mutant ataxin-1 protein (ATXN1)
causes loss of cerebellar Purkinje cells (PC) and dysfunction and degeneration in the cerebellum,
brain stem, and spinal cord. To date, treatment consists of managing the symptoms with
pharmacologic agents. No fundamental therapies for SCA 1 have been identified yet (Whaley et al.,
2011), although several experimental studies have shown promising results.
This review will provide background information on SCA 1 and the mouse models used as well
as inform the reader about promising gene and stem cell therapy approaches. Challenges regarding
these novel approaches will be discussed and other alternative therapies will be briefly reviewed.
FACTS AND DEMOGRAPHICS
According to the National Ataxia Foundation, approximately 1–2 in 100,000 people will develop
SCA 1, but the frequency varies depending on ethnic background and location (National Ataxia
Foundation, https://www.ataxia.org/).
The onset of the disease begins around the 3rd–4th decade but can develop between the ages of
4 and 74 (Schols et al., 2004). From onset, patient survival ranges from 10 to 28 years (average= 15
years; Jayadev and Bird, 2013). In cases of early onset (before 13 years old), disease progression
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TABLE 1 | Autosomal dominant hereditary ataxias.
Disease Namea Gene Average onset (range in years) Average duration
(range in years)
Distinguishing featuresb
SCA1 ATXN1 3rd–4th decade (<10 to >60) 15 years (10–28) Pyramidal signs, peripheral neuropathy
SCA2 ATXN2 3rd–4th decade (<10 to >60) 10 years (1–30) Slow saccadic eye movements, peripheral neuropathy, decreased
DTRs, dementia
SCA3 ATXN3 4th decade (10–70) 10 years (1–20) Pyramidal and extrapyramidal signs; lid retraction, nystagmus,
decreased saccade velocity; amyotrophy fasciculations, sensory
loss
SCA4 16q22.1 4th–7th decade (19–72) Decades Sensory axonal neuropathy, deafness; may be allelic with 16q22-
linked SCA
SCA5 SPTBN2 3rd–4th decade (10–68) >25 years Early onset, slow course; first reported in descendants of
Abraham Lincoln
SCA6 CACNA1A 5th–6th decade (19–71) >25 years Sometimes episodic ataxia, very slow progression
SCA7 ATXN7 3rd–4th decade (0.5–60) 20 years (1–45; early
onset correlates with
shorter duration)
Visual loss with retinopathy
SCA8 ATXN8I 4th decade (1–65) Normal life span Slowly progressive, sometimes brisk DTRs, decreased vibration
sense; rarely, cognitive impairment
ATXN80S
SCA10 ATXN10 4th decade (12–48) 9 years Occasional seizures; most families are of Native American
background
SCA11 TTBK2 Age 30 years (15–70) Normal life span Mild, remain ambulatory
SCA12 PPP2R2B 4th decade (8–62) Slowly progressive ataxia; action tremor in the 30s; hyperreflexia;
subtle Parkinsomism possible; cognitive/psychiatric disorders
including dementia
SCA13 KCNC3 Childhood or adulthood Unknown Mild intellectual disability, short stature
SCA14 PRKCG 3rd–4th decade (3–70) Decades (1–30) Early axial myoclonus
SCA15 ITPR1 4th decade (7–66) Decades Pure ataxia, very slow progression
SCA16 SCA16 Age 39 years (20–66) 1–40 years Head tremor; one Japanese family
SCA17 TBP 4th decade (3–55) >8 years Mental deterioration; occasional chorea, dystonia, myoclonus
SCA18 7q22-q32 Adolescence (12–25) Decades Ataxia with early sensory/motor neuropathy, nystagmus,
dysarthria, decreased tendon reflexes, muscle weakness, atrophy,
fasiculations, Babinski responses
SCA 19/22 KCND3 4th decade (10–51) Decades Slowly progressive, rare cognitive impairment, myoclonus,
hyperreflexia
SCA20 11q12.2 5th decade (19–64) Decades Early dysarthria, spasmodic dysphonia, hyperreflexia,
bradykinesia; calcification of the dentate nucleus
11q12.3
SCA21 SCA21 6–30 Decades Mild cognitive impairment
SCA23 PDYN 5th–6th decade >10 years Dysarthria, abnormal eye movements, reduced vibration and
position sense; one Dutch family; neuropathology
SCA25 SCA25 (1.5–39) Unknown Sensory neuropathy; one French family
SCA26 EEF2 (26–60) Unknown Dysarthria, irregular visual pursuits; one Norwegian-American
family; MRI: cerebellar atrophy
SCA27 FGF14 Age 11 years (7–20) Decades Early-onset tremor; dyskinesia, cognitive deficits; one Dutch family
SCA28 AFG3L2 Age 19.5 years (12–36) Decades Nystagmus, opthalmoparesis, ptosis, increased tendon reflexes;
two Italian families
SCA29 3p26 Early childhood Lifelong Learning deficits
SCA30 4q34.3–q35.1 (45–76) Lifelong Hyperreflexia
SCA31 BEAN1 5th–6th decade Lifelong Normal sensation
SCA35 TGM6 43.7 ± 2.9 (40–48) years 15.9 ± 8.8 (5–31)
years
Hyperreflexia, Babinski respsonses; spasmodic torticollis
SCA36 NOP56 52.8 ± 4.3 years Decades Muscle fasiculations, tongue atrophy, hyperreflexia
DTR, deep tendon reflex.
aSCA9 has not been assigned.
bAll have gait ataxia.
Reprinted by permission from Macmillan Publishers Ltd: Genetics in Medicine (Jayadev and Bird, 2013), copyright (2013).
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 August 2016 | Volume 9 | Article 67
Wagner et al. Therapies for SCA 1
is more rapid and severe, with patients usually dying before the
age of 16 (Zoghbi et al., 1988).
Clinically, SCA 1 symptoms include limb ataxia, gait
disturbance, slurred speech, balance difficulty, brisk tendon
reflexes, hypermetric saccades, nystagmus, mild dysphagia, and
cognitive impairment. SCA 1 symptoms can be distinguished
from other hereditary ataxias by the predominance of pyramidal
symptoms. Amyotrophy and sensory loss can also be present in
affected individuals. Olivopontocerebellar atrophy is the major
finding on MRI/CT (Schols et al., 2004). Eventually, affected
individuals develop respiratory failure, the main cause of death
for SCA 1 (Subramony and Ashizawa, 1993).
MOLECULAR PATHOGENESIS
SCA 1 is caused by a CAG repeat expansion in the ATXN1 gene
(OMIM: 601556) that encodes ATXN1. In normal ATXN1, the
triplet CAG is repeated 6 to 36 times while in mutant forms
(polyQ-ATXN1) the number of repeats can exceed 100. Similar
to other polyglutamine (polyQ) diseases such as Huntington’s, as
the polyQ expansion becomes longer, disease onset occurs earlier,
and the symptoms are more severe (Kang and Hong, 2009). The
polyQ expansion is thought to be due to errors in the DNA
replication machinery (Kang et al., 1995). The number of repeats
can increase from generation to generation, particularly in the
paternal germline (Matilla et al., 1993).
ATXN1 is mainly localized to the nucleus of neuronal cells;
however, in Purkinje cells, it is found in both the cytoplasm
and the nucleus (Servadio et al., 1995). It associates with a
collection of high molecular weight protein complexes that also
contain Capicua (CIC), a transcriptional repressor containing
a high mobility group (HMG) box. The presence of human
polyQ-ATXN1 alters the size distribution of these complexes and
inhibits the repressor activity of CIC. Overexpression of CIC
in a fly model suppresses the morphologic changed induced by
polyQ-ATXN1 (Lam et al., 2006). Additionally, Yue et al. found
that ATXN1 binds RNA and that, as size of its polyQ tract
increases, its ability to bind RNA decreases. Thus, expansion of
the ATXN1 polyQ tract may alter its role in RNA metabolism
(Yue et al., 2001). polyQ-ATXN1 aggregates and forms inclusions
in the nucleus and cytoplasm of neurons, especially in PCs
(Kang and Hong, 2009). PolyQ-ATXN1 alters several cellular
pathways, including transcription (Cvetanovic et al., 2007; Lee
S. et al., 2008), RNA processing (Hong et al., 2003), and signal
transduction (Goold et al., 2007; Gatchel et al., 2008), disrupting
normal cell function and leading to cell death (Kang and Hong,
2009).
Phosphorylation contributes to the regulation of ATXN1
folding and distribution. Emamian et al. found that serine
776 (S776) was phosphorylated in transgenic mice carrying
ATXN1. Mutating S776 to alanine altered the intracellular
deposition of polyQ-ATXN1, preventing nuclear inclusions from
forming. When the S776 and A776 forms of polyQ-ATXN1
(polyQ-ATXN1-S776 and polyQ-ATXN1-A776, respectively)
were expressed in Purkinje cells in mice, polyQ-ATXN1-
A776 was substantially less toxic than polyQ-ATXN1-S776,
demonstrating that phosphorylation of this serine residue
contributes significantly to the harmful effects of the mutant
protein (Emamian et al., 2003). The protective effect of A776
appears to be due to the fact that polyQ-ATXN1-A776 does
not produce the abnormal, high molecular weight complexes
that are observed in mice carrying polyQ-ATXN1-S776, even
though both forms associated strongly with CIC. Interestingly,
it appears that toxicity arises, not due to novel interactions
between polyQ-ATXN1 and other proteins, but from polyQ-
ATXN1 adversely affecting the function of proteins it normally
interacts with (Lam et al., 2006). Protein Kinase A (PKA) is the
cAMP-dependent kinase responsible for S776 of ATXN1 (Chen
et al., 2003; Jorgensen et al., 2009). In addition to S776, Vierra-
Green et al. found through matrix-assisted laser description
ionization time-of-flight mass spectrometry (MALDI TOF) and
mutational analysis that S239 is also a phosphorylation site of
ATXN1 (Vierra-Green et al., 2005), although further research is
required to determine if S239 is linked to SCA 1 pathogenesis.
Understanding the phosphorylation of ATXN1 allows for a better
understanding of the role ATXN1 has within neurons, specifically
with post-translational modifications, which is vital for future
therapeutic strategies.
Relevant to polyQ-ATXN1 cytotoxicity, Lee et al. found
that ATXN1 levels might be post-transcriptionally regulated
by miRNA, specifically miR-19, miR-101, and miR-130. When
miR-19, miR101, and miR130 were transfected into HEK293T,
HeLa and MCF7 cells, a marked decrease in ATXN1 levels was
observed. When 2′-O-methyl inhibitors against the miRNA were
added to HEK293T cells, ATXN1 levels increased. These findings
present the possibility that miRNA-binding site mutations or
miRNA genes might lead to the SCA 1 neurodegenerative
phenotypes (Lee Y. et al., 2008).
MOUSE MODELS
Mouse models have been generated to study the cerebellar
degeneration associated with SCA 1. In the B05 transgenic
mouse model (B05) the human SCA 1 cDNA was modified to
contain 82 CAG repeats and expressed under the control of the
Purkinje cell protein 2 (pcp2) promoter to form a pcp2/SCA1
transgene. The 5′ regulatory sequences of pcp2 are sufficient
to restrict transgene expression to PCs (Oberdick et al., 1990;
Vandaele et al., 1991). B05 transgenic mice overexpress polyQ-
ATXN1, which leads to the loss of PCs from the cerebellum and
thus present the neurological phenotype of ataxia. Abnormalities
include reduced activity, head swaying and incoordination.
Ataxia onset begins at 12 weeks of life. However, because the
mutant cDNA is only expressed in Purkinje cells, this model
only displays symptoms of degenerating PCs and these mice
have a normal life span (Burright et al., 1995). Patients, in
contrast, experience dysfunction in a variety of neurons in
addition to PCs (Bürk et al., 2001). These other neurons produce
cognitive dysfunction that is not represented in the B05 mouse
model (Table 2), which makes comparisons to SCA 1 patients
difficult.
To better model SCA 1, Watase et al. generated a SCA 1
knock-in model by introducing a 154-CAG expansion into exon
8 of the endogenous ATXN 1 locus. The knock-in mouse model,
called Sca1 154Q/2Q (154Q/2Q), expresses polyQ-ATXN1 in
neurons in the cortex, thalamus, hypocampus, caudate nucleus,
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putamen, brain stem, cerebellum, and spinal cord. With polyQ-
ATXN1 allele present throughout the central nervous system,
the 154Q/2Q model displays more of the human disease
features, such asmotor incoordination, muscle wasting, cognitive
impairment, and premature death, making it a more relevant
physiological model of the disease. Disease onset begins at 7–8
weeks and mice die prematurely at 35–45 weeks of age (Watase
et al., 2002; Table 2).
No non-rodent animal model exists for SCA 1. A transgenic
model of Huntington’s disease, another polyQ disease involving
an expanded polyglutamine repeat in HTT, exists in rhesus
macaque (Yang et al., 2008), suggesting that a SCA 1 model could
be made as well.
GENE THERAPY
SCA 1 is a monogenic disease; thus, gene therapy is an obvious
treatment approach. Gene therapeutic intervention involves
either reducing expression of the mutant ATXN1 through gene
silencing or overexpressing a paralog of ATXN1, ataxin-1-
like (ATXN1L), to competitively inhibit the formation of toxic
complexes by polyQ-ATXN1 (Keiser et al., 2013).
The RNAi approach regulates gene expression through
small RNAs, including artificial microRNA (miRNA), small
interfering RNA (siRNA), and short hairpin RNA (shRNA).
Short hairpin RNA, siRNA, and miRNA are all non-coding
RNA that post-transcriptionally regulate mRNA transcript levels.
siRNA acts on a particular sequence for degradation while
miRNA is more likely to target mRNA for transcriptional
silencing (Lam et al., 2015). Unlike siRNA which requires two
independent RNA strands, a sense and antisense strand that
guides the RNA-induced silencing complex (RISC), shRNA is
a single strand that folds back on itself to produce a double-
stranded molecule (Davidson and Paulson, 2004). The Davidson
research group showed that RNAi platforms (Keiser et al., 2013)
expressed using viral vectors could potentially have therapeutic
effects on polyglutamine diseases. Xia et al. investigated the
possibility that virally expressed siRNA could decrease levels of
polyglutamine expanded proteins in neural PC12 clonal cells.
The lines were developed to express tetracycline-repressible
eGFP-polyglutamine fusion proteins, which the siRNA targeted.
Decrease in protein aggregate levels was shown by western
blot analysis and cellular fluorescence (Xia et al., 2002;
Table 3).
RNA interference (RNAi) has already been proven to be
effective in a number of diseases caused by CAG repeat
expansion. Harper et al. injected AAV2/1 targeting huntingtin
(HTT) intracranially and found reduced HTT mRNA levels
and protein expression in HTT transgenic mice. Mice showed
improved behavioral outcomes and reduced neuropathic HTT
abnormalities (Harper et al., 2005). Additionally, Monteys et al.
found preferential silencing of the mutant HTT allele in vitro
by miRNA. Preferential knockdown of the mutant allele was
achieved in vivo when one of the miRNAs tested was delivered
through AAV2 by striatal bilateral injection into HTT double
transgenic mice, However, knockdown of the wild-type allele
was also detected (Monteys et al., 2015). Miller et al. generated
siRNA that silences the SCA 3-associated allele, ataxin-3
(ATXN3), targeting an adjacent single nucleotide polymorphism
(SNP). In vitro, the RNAi approach successfully silenced
both plasmid and viral expression of ATXN3 (Miller et al.,
2003). In vivo, AAV2 vector was delivered via intracerebellar
injection into SCA 3 mice. Rodriguez-Lebron et al. found
that anti-ATXN3 miRNA suppressed ATXN3 expression and
cleared nuclear accumulation of mutant ATXN3 (Rodriguez-
Lebron et al., 2013). Lastly, for SCA 7, Ramachandran
et al. found more than 50% reduction of mutant human
and wildtype mouse ATXN7 allele after AAV2/1 subretinal
space injection of miRNA into SCA 7 transgenic mice. Mice
preserved normal retinal function after injection (Ramachandran
et al., 2014). Keiser et al. found that ATXN1 levels can
be reduced 30% by miS1 knockdown through AAV1 deep
cerebellar nuclei injection in an adult rhesus. The intervention
was well tolerated and there were no clinical complications.
The biodistribution and tolerability of the miS1 treatment
supports its use as a clinical therapeutic (Keiser et al., 2015;
Table 3).
Xia et al. tested shRNA to target the Sca 1 locus. They
generated AAV serotype 2/1 (AAV 2/1) that expressed shRNA
which was delivered via intracerebellar injection. This treatment
resolved ATXN1 nuclear inclusions and PC morphology as
well as improving motor coordination in transgenic B05 mice
TABLE 2 | Overview of mouse models for SCA 1.
B05 transgenic mice (B05) Sca1 154Q/2Q mice (154Q/2Q)
Phenotype Motor incoordination, ataxia (12 weeks), no cognitive impairment motor incoordination, muscle wasting, cognitive impairment, memory
deficits
Physical Onset 5 weeks 7–8 weeks
Course of the disease Normal life span Premature, 35–45 weeks
Neuropathology PC loss, Bergmann glial proliferation, shrinkage and gliosis of molecular
layer
Reduced dendritic arborization of PCs (early stage)
Neuronal intranuclear inclusions and PC loss (advanced disease)
Purkinje neuron dendritic and somatic atrophy Hypocampal synaptic dysfunction but no significant loss
Mechanism Overexpression of polyQ-ATXN1 (82 CAG repeats) under the control of
Purkinje Cell pcp2 promoter
Expanded repeat of 154 CAGs was inserted into the mouse Sca 1 locus
(knock-in)
References Burright et al., 1995; Clark et al., 1997 Watase et al., 2002
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TABLE 3 | Overview of gene therapies for SCA 1.
Treatment/vector Animal model Route Outcome
Keiser et al., 2013 (1) miRNA/AAV serotype 2/1 B05 mice DCN injection Widespread PC transduction
(2) Atxn1 Like/AAV serotype 2/1 Improved histology and
behavioral profiles
Xia et al., 2004 siRNA/AAV2 B05 mice Direct injection into the cerebellar
lobules
Cerebellar morphology
restoration, PC inclusions
resolution, improved motor
coordination
Keiser et al., 2014 RNAi/AAV serotype 2/5 SCA1 154Q/2Q knock-in mice Deep cerebellar nuclei (DCN) Preserved neurohistology and
rotarod performance
Venkatraman et al., 2014 HDAC 3 depletion (1) PC-specific HDAC3 null
knock-in mice
N/A (1) No improvement in cognitive
and cerebellar function
(2) SCA1 154Q/2Q mice
(heterozygous HDAC3+/− mice)
(2) Deleterious effects both
behaviorally and histologically
(Xia et al., 2004). Keiser et al. tested the therapeutic utility of
SCA 1-targeted AAV 2/1 miRNA to suppress ATXN1 expression.
The construct was delivered via deep cerebellar nuclei injection
and resulted in PC transduction and improved gait and balance
in transgenic B05 mice (Keiser et al., 2013). To our knowledge,
siRNA or shRNA targeting ATXN1 has not been evaluated
in 154Q/2Q mice. Keiser et al. found that miRNA therapy
in 154Q/2Q mice was sufficient to reduce SCA 1 symptoms.
They tested the efficacy of miRNA delivered via AAV 2/5 to
the deep cerebellar nuclei. The RNAi inhibited SCA 1-related
transcriptional changes, preserved the cerebellar lobule, and
improved motor coordination (Keiser et al., 2014; Table 3).
The potential toxicity of small RNA should be noted. Grimm
et al. studied the long-term effect of high shRNA expression in
the livers of mice through AAV8 intravenous infusion. Of the
49 AAV/shRNA vectors tested, 36 caused does-dependent liver
injury, with 23 of those leading to death. Grimm et al. found
the morbidity to be associated with downregulation of miRNAs
derived from the liver, possibly indicating competition with the
shRNAs (Grimm et al., 2006). The study demonstrates the risk of
oversaturating small RNA pathways with RNAi therapy.
As an alternate approach to RNAi, overexpression of the
ATXN1L protein also represents a feasible therapy for SCA 1.
ATXN1 and ATXN1L interact with a similar set of proteins,
including CIC, through their ATXN1 and HMG-box protein
1 domain (AXH domain). Overexpression of ATXN1L could
outcompete polyQ-ATXN1 for binding to CIC, reducing the
amount of toxic complexes and disease severity (de Chiara et al.,
2003; Lam et al., 2006; Bowman et al., 2007; Lim et al., 2008).
Keiser et al. showed that overexpression of ATXN1L from an
AAV2/1 vector has protective effects in B05 mice. In their study,
human ATXN1L was expressed using AAV 2/1 and was delivered
into the deep cerebellar nuclei. Mice receiving the injection
exhibited improved gait, agility, and hind limb musculature and
also decreased nuclear inclusions and PC loss, similar to that
observed with the miRNA. Keiser et al. concludes that both
overexpression of ATXN1L and RNAi are potentially viable
treatment options for SCA 1 patients (Keiser et al., 2013;Table 3).
Alternatives to targeting the gene directly through RNAi
and ATXN1L include histone deacetylase transcriptional
repression. ATXN1 binds HDAC3, a class 1 histone deacetylase
(HDAC) required for ATXN1 induced transcriptional repression
(Karagianni and Wong, 2007). Venkatraman et al. tested the
effect of PC-specific HDAC3 depletion in 154Q/2Q mice by
siRNA knock down. However, mice did not show improvement
in cerebellar or cognitive function. Additionally, Venkatraman
et al. crossed a floxed HDAC3 mouse line with a mouse driving
Cre expression from a pcp-2 promoter. The pcp-2 promoter turns
on 6 days after birth in PC cells and reaches a maximum by 2–3
weeks after birth, which is about the time that transcriptional
problems manifest (Lin et al., 2000; Gatchel et al., 2008). The
offspring line has a conditional complete loss of HDAC3 in PCs
and demonstrated dramatic PC degeneration and early onset
ataxia. These results warn of the risk of neurotoxic side effects
that can be caused by altering HDAC3 expression to treat SCA 1
(Venkatraman et al., 2014; Table 3).
In our opinion of the gene therapies, RNAi knockdown treats
the cause of the disease while ATXN1L might not, as the polyQ-
ATXN1 aggregates are still present. On the other hand, this
cannot be definitive known until a side by side comparison
between ATXN1L and RNAi with stringent control of the
conditions is performed. Additionally, the issue of small RNA
oversaturation arises. As with most gene therapies, the question
also remains, is there adequate transduction of the therapeutic
into the affected cells?
STEM CELL THERAPY
Stem-cell-based therapies represent a new strategy for
spinocerebellar ataxias. Neurotransplantation has been
performed in various cerebellar mutant mice using different
types of cells and delivery techniques to stop PC degeneration
and restore normal cerebellar architecture. Currently, a few
studies have tried stem cell transplantation in SCA 1 mouse
models and showed positive results both functionally and
histologically.
An interesting approach by Chen et al. combines stem cell
and gene therapy for gene delivery in SCA 1 mice. Bone
marrow-derived cells (BMDCs) can fuse in vivo with somatic
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 August 2016 | Volume 9 | Article 67
Wagner et al. Therapies for SCA 1
cells, including Purkinje neurons (Alvarez-Dolado et al., 2003;
Weimann et al., 2003). Bone marrow derived cells (BMDC)
were genetically modified using AAV7 to carry two SCA 1
modifier genes, DnaJB4 and Pcbp3. The genes were determined
by Fernandez-Funez et al. to have attenuating effects on
SCA 1 onset by assisting chaperone activity and transcription
stabilization, respectively (Fernandez-Funez et al., 2000). Chen
et al. delivered BMDC by a retroorbital sinus injection into
154Q/2Q mice. PC and BMDC fused to produce heterokaryons
with PC properties. In the treated 154Q/2Qmice, there was some
improvement in pathology. Mice showed a diminished number
of nuclear inclusions and an increased number of surviving
PC, highlighting the potential neuroprotective effects of this
combined strategy (Chen et al., 2011; Table 4).
Chintawar et al. transplanted neural precursor cells (NPCs)
from the subventricular zone of adult mice to cerebellar white
matter of B05 mice. Mice received injections into three separate
sites of the cerebellar white matter at 5-, 13-, or 24-weeks-old
time points where cerebellar pathology is not yet observed, PC
loss begins, and PC are mostly abnormal, respectively. Grafted
NPCs only migrated to the cerebellar cortex in 24-week-old mice.
Additionally, motor skills only improved in mice treated at 24
weeks when compared to shams.When grafted NPCs didmigrate
to the cerebellar cortex, grafts did not adopt PC characteristics,
but NPC-grafted B05 mice did exhibit thicker molecular layer
and diminished PC loss (Chintawar et al., 2009; Table 4).
Matsuura et al. found that intrathecal injection of
mesenchymal stem cells (MSCs) into the meningeal covering of
the cerebellum improved PC organization in B05 mice injected at
5 weeks of age. At 24 weeks of age, untreated B05 mice displayed
multilayered PC as a result of ectopically located PC bodies, but
mice of the same age injected with MSCs had monolayered PCs.
Additionally, MSC treatment reduced PC dendrite atrophy and
normalized behavior and motor deficits (Matsuura et al., 2014;
Table 4).
Stem cell therapies on non-SCA 1 mouse models are
relevant to mention. In Lercher mutant mice, a mouse model
characterized by the selective early post-natal death of PCs in
the cerebellum, Jones et al. found that bone marrow-derived
mesenchymal stem cells injected into the cerebellum migrated
throughout the cerebellum. Their results showed an increase in
the number of surviving PCs due to the neurotrophic factors
released by adjacent grafted cells as well as an improvement in
motor function (Jones et al., 2010).
Stem cell therapy in SCA 2 mice has also proven successful.
Human MSC were delivered intravenously at 12, 23, 33, and 42
weeks of age (disease onset for untreated mice was 33–40 weeks
of age). The injections resulted in a delay in the onset of motor
function deterioration. In the same study, human MSC were
injected into the cerebellum through the foramen magnum both
before and after motor function loss but, unlike the intravenous
route, there was no improvement (Chang et al., 2011).
Two clinical trials have looked at the safety and efficacy
of stem cell transplantation in SCA. In a phase I/II trial, Jin
et al. intrathecally and intravenously infused human umbilical
cord mesenchymal stem cells (UC-MSC) into 16 patients with
genetically diagnosed SCA 1, 2, or 3. Results showed that no
serious transplantation side effects occurred during the 12 month
follow-up period. Berg Balance Scale (BBS) and International
Cooperative Ataxia Rating Scale (ICARS) scores improved for at
least 6 months following the transplantation. Results were scored
by a blinded neurologist (Jin et al., 2013) (NCT01360164).
Dongmei et al. also studied the effect of intrathecal injection
of umbilical cord mesenchymal stem cells (UC-MSC) in 14
patients with SCA. The types of SCA were not specified.
Serial weekly injection, with four injections total, significantly
improved Activity of Daily Living Scale (ADL), and ICARS
scores. ICARS and ADL scores decreased significantly 1 month
after treatment. For follow-up, 8 patients remained stable for an
average period of 9 month and 6 progressed after treatment with
average stabilization of 4 months (Dongmei et al., 2011).
These studies may represent a proof of principle of the
therapeutic potential of stem cells in SCA. However, both
trials were open label, and substantial placebo effects cannot
be discounted. Further clinical studies including more patients
need to be performed in order to better assess safety and
efficacy.
ALTERNATIVE THERAPIES
While gene and stem cell therapies are currently most prominent,
many alternative therapies, including protein delivery, are also
potentially relevant treatments for SCA 1. Main approaches
TABLE 4 | Overview of stem cell therapies for SCA 1.
Mouse model Type of stem cells Route Histology results Functional results
Chen et al., 2011 SCA1 154Q/2Q mice BMDC (genetically
modified using AAV7 to
carry SCA 1 modifier
genes)
Right retro-orbital sinus
injection
Diminished nuclear
inclusions, increased
number of surviving PC
Not assessed
Chintawar et al., 2009 B05 transgenic mice Subventricular zone
derived NPCs
Stereotactic cerebellar
white matter microinjection
Thicker molecular layer. Improved motor skills
Diminished PC loss Normalized behavior
Matsuura et al., 2014 B05 transgenic mice Bone marrow derived MSC Intrathecal injections Suppression of PC
dendrites atrophy
Improved motor
coordination
Thicker molecular layer
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include vascular endothelial growth factor (VEGF), cAMP-
dependent protein kinase A (PKA) inhibitory polypeptide, and
3,4-diaminopyridine.
Cvetanovic et al. found that vascular endothelial growth
factor (VEGF) improves the SCA 1 phenotype in 154Q/2Q
mice. VEGF is an angiogenic and neurotrophic factor, and it
is down-regulated in SCA 1 mice. Cvetanovic et al. crossed
154Q/2Q mice with transgenic mice that overexpress VEGF.
These mice exhibited thicker molecular layers and improved
motor performance. This study went further to show the positive
effect that recombinant VEGF has on 154Q/2Qmice. As it cannot
cross the blood brain barrier (BBB), an intracerebroventricular
osmotic pump was inserted subcutaneously into 11-week-old
mice to deliver VEGF via a catheter into the right lateral ventricle
over 2 weeks. Mice with the pump exhibited thicker molecular
layers and improved motor performance. The authors proposed
that VEGF could be a biomarker for human disease progression
(Cvetanovic et al., 2011; Table 5).
PC degeneration in SCA 1 is enhanced by the phosphorylation
of S776 of polyQ-ATXN1 by PKA (Chen et al., 2003; Emamian
et al., 2003; Jorgensen et al., 2009). Hearst et al. (2014a)
engineered a PKA inhibitory polypeptide to prevent the
formation of nuclear inclusions. The PKA inhibitory polypeptide
(Synb1-ELP-PKI) is composed of a cell-penetrating peptide
(Synb1), a heat responsive elastin-like peptide (ELP) carrier to
increase peptide half-life, and a PKA inhibitory peptide (PKI).
Using B05 mice, Synb1-ELP-PKI was delivered through the
intraperitoneal or intranasal injection route. Both routes allowed
the peptide to successfully cross the BBB and localize in the
cerebellum. Mice showed decreased intranuclear inclusions and
improved PC morphology. Motor function was not assessed
(Hearst et al., 2014a; Table 5).
Hourez et al. (2011) found that aminopyridines might have
positive neuroprotective and symptomatic effects for SCA 1. 3,4-
diaminopyridine is an organic compound that blocks potassium
channels and is used to treat neuronal dysfunction (Kirsch and
Narahashi, 1978). Before SCA 1 symptoms present, B05 mice
show reduced PC firing rate. Acute subcutaneous injection of
3,4-diaminopyridine in young B05 mice normalized the firing
rate of PCs and improved motor function. Chronic subcutaneous
injection, partially prevented PC atrophy. This effect was
associated with increased brain-derived neurotrophic factor
(BDNF), suggesting that protection against atrophy is possibly
carried out by BDNF, which occurs secondary to the return
of electrical activity (Hourez et al., 2011; Table 5). Adding to
the argument that aminopyridines increase PC firing frequency,
(Alviña and Khodakhah, 2010) reported that 4-aminopyridine
restored pacemaking precision in the PCs in a mouse model
of episodic ataxia 2 (Alviña and Khodakhah, 2010). A clinical
trial of 4-aminopyridine (dalfampiridine) was completed in 2014.
In a crossover study 20 patients with either SCA 1, 2, 3, or 6
received an oral dose of 4-aminopyridine for 4 weeks and 4
weeks of placebo with a 2 week washout period in between.
One patient had adverse effects to the drug. Results showed that
4-aminopyridine did not significantly improve performance on
the Timed 25 Feet Walking Test, the Scale of Assessment and
Rating of Ataxia (SARA), or the Biomechanical Assessment of
Gait–Stride Length (NCT01811706).
Other alternatives strategies that are less invasive, including
whole body vibration (WBV), heat shock protein (HSP)
stimulation, and oral doses of lithium, have also shown promising
results and could be used alone or as an adjunct to other
treatments. Kaut et al. investigated the effect of stochastic whole
body vibration on SCA 1, 2, 3, and 6 patients in a double
blind sham controlled study. WBV stimulates the neuromuscular
system through vibration, and it has already shown to improve
balance and mobility in patients with Parkinson’s (Haas et al.,
2006). WBV was applied on 4 sequent days, the treatment
consisting of five stimulus trains of 60 s duration at a frequency
of 6.5 Hz and 60 s resting time between stimuli. The sham
group received the same treatment with a frequency of 1 Hz.
Improvements in gait, posture, and speed of speech were seen but
no response in limb kinetics and ataxia of speech was observed
(Kaut et al., 2014). However, it is necessary to mention a Huang
TABLE 5 | Overview of other therapies for SCA 1.
Treatment Animal model Route Outcome
Cvetanovic et al.,
2011
VEGF 154Q/2Q mice Pharmacologic:
intraventricular infusion
Improved pathological hallmarks and motor function
Transgenic: gene
over-expression
Hearst et al., 2014a PKA inhibitory polypeptide
(Synb1-ELP-PK)
B05 mice Intraperitoneal/intranasal Decreased intranucelar inclusions, improved PC morphology
Hourez et al., 2011 3,4-diaminopyridine B05 mice Subcutaneous injection Normalized PC firing rate, reduced PC atrophy, improved
motor function
Hearst et al., 2014b Focused Laser Light
Hyperthermia
B05 mice Cerebellar Hsp70 production, suppressed PC loss, improved motor
function
Watase et al., 2002 Lithium 154Q/2Q Dietary Improved motor coordination, learning, and memory.
Increased Dendritic branching in hippocampal pyramidal
neurons
Perroud et al., 2013 Lithium 154/2Q Dietary Increased metabolic processes, specifically higher purine levels
Iizuka et al., 2015 Memantine 154Q/2Q Dietary Attenuated PC loss and vagus motor neuron loss. Extended
life span and reduced weight loss
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et al. (2014) review of WBV trials. The review states that there
is insufficient evidence to support or negate if WBV can reduce
symptoms in SCA among other diseases claiming more trials
need to be performed with better methodological and reporting
quality.
Hearst et al. (2014b) based on the neuroprotective role of
chaperone HSPs known to modulate polyglutamine protein
aggregation, explored the effects of focused laser light induced
hyperthermia (HT) on HSP-mediated protection against ATXN1
toxicity in both cell culture model and transgenic mice. This
study revealed that mild cerebellar HT stimulated the production
of Hsp70 to a significant level and markedly suppressed the
SCA 1 phenotype and PC loss as compared to sham-treated
control animals (Hearst et al., 2014b). The nuclear inclusions
in PCs stain positive for Hsp70 and Hsp40, ubiquitin and
proteasomal subunits. Over expression of HDJ-2, an Hsp40
chaperone reduces protein aggregation (Cummings et al., 1998).
Cummings et al. went on to find that overexpression of Hsp70
chaperone suppresses neuropathy and improves motor function
in B05 mice (Cummings et al., 2001).
Lithium treatment has the potential to reduce SCA 1
symptoms in humans. A Watase et al. study showed that dietary
lithium treatment resulted in improved motor coordination as
well as learning and memory in 154Q/2Q mice. At 10 weeks of
age, motor improvement was noted both in mice that received
the treatment pre-symptomatically and post-symptomatically.
Lithium treatment increased dendritic branching in mutant
hippocampal pyramidal neurons (Watase et al., 2007). Perroud
et al. also found that lithium treatment improved the motor
coordination of 154Q/2Q mice. Mice receiving lithium exhibited
increased metabolic processes, particularly higher purine levels.
Perroud et al. propose that purine metabolites might have a
neuroprotective effect (Perroud et al., 2013). Lithium is involved
in a large number of cell processes; it is not clear what
combination is alleviating the symptoms. A human phase I trial
of oral lithium was completed in 2010; results have yet to be
published (NCT00683943).
Memantine, a low-affinity non-competitive N-methyl-d-
aspartate (NMDA) receptor antagonist is a possible drug. Iizuka
et al. orally administered memantine to 154Q/2Q mice from 4
weeks old to death. Mice receiving the treatment lived longer
and did not lose as much weight as typical 154Q/2Q mice.
Mice receiving memantine had attenuated PC loss as well as
motor neuron loss in the dorsal motor nucleus of the vagus.
The study claims that these results exhibit that activation of
extrasynaptic NMDA receptors lead to neuronal cell death in
154Q/2Q mice (Iizuka et al., 2015). However, the study fails to
show the effect of memantine on SCA 1 symptoms is through
its role as an NMDA antagonist. Memantine also affects the
dopamine (Seeman et al., 2008), serotonin (Rammes et al., 2001),
and acetyl choline receptors (Aracava et al., 2005) which would
complicate its use as a SCA 1 therapy. Memantine has potential
as a SCA 1 therapeutic but the mechanism of action needs to be
better understood.
Glial cells have not received as much attention as neuronal
pathology in SCA 1 studies, despite reports of gliosis in the
brains of deceased SCA 1 patients (Genis et al., 1995; Gilman
et al., 1996). In many neurological diseases, such as Amyotrophic
Lateral Sclerosis and Parkinson’s disease, astrocyte and microglia
activation changes, including proinflammatory cytokine release,
can reduce neuronal survival (Glass et al., 2010). Cvetanovic et al.
observed hypertrophy of Bergmann glia, a sub-type of astrocyte
that is located near Purkinje neurons, in 154Q/2Q mice using
Glial Fibrillary Acidic Protein (GFAP). Hypertrophy was noticed
in the presymptomatic period of the 154Q/2Q model at 8 weeks
old, and the GFAP staining increased with disease progression.
Cvetanovic et al. also observed hypertrophy of microglia cells
in 154Q/2Q mice by staining for ionized calcium-binding
adapter molecule 1 (Iba1). Like the Bergmann glia, microglia
hypertrophy began at 8 weeks of age and increased with disease
progression. Additionally, Cvetanovic et al. found glial activation
occurs presymptomatically in B05 mice where only Purkinje
neurons express ATXN1. Pro-inflammatory cytokine micro
RNA levels increased alongside glial levels as well (Cvetanovic
et al., 2015). Cvetanovic has recently received funding from
the National Ataxia Foundation to test PLX3397, a drug that
removes microglia from the brain without adverse effects in
mice under laboratory conditions (Elmore et al., 2014), as a
therapeutic.
TREATMENTS USED IN OTHER SCA
TYPES
Two treatments currently being tested in other forms of SCA
are worthy of mention, specifically Rhophylax, an IgG, and
Dantrolene, a ryanodine-receptor inhibitor. Both therapies have
the potential to be tested on SCA 1 as well.
It is believed that inflammation may contribute to neuronal
dysfunction, although the pathophysiology is not known.
Evert et al. (2001) found upregulation of mRNAs encoding
metalloproteinase 2 (MMP-2), an endopeptidase matrix,
the cytokine stromal cell-derived factor 1α (SDF1α), the
transmembrane protein amyloid precursor protein, and the
interleukin-1 receptor-related Fos-inducible transcript in SCA
3 mice. Immunohistochemical analysis of human SCA 3 brain
tissue found increased expression of MMP-2 and amyloid β-
protein (Aβ) in pontine neurons containing nuclear inclusions.
Additionally, increased numbers of astrocytes and microglial
cells were found in the pons of SCA 3 patients (Evert et al.,
2001). In light of these results, a clinical trial is being initiated
to administer intravenous immune globin (IVIG)- Rhophylax,
an IgG, to SCA 1, 2, 3, 6, 10, and 11 patients to observe how
the drug effects SCA symptoms as well as nerve and motor
function (NCT02287064). In the pilot for the clinical trial, three
patients received three courses of IVIG-Rhophylax at 2 grams/
kilogram body weight over 5 days. Courses were 4 weeks apart.
The patients in the pilot had SCA 3, SCA 5, or sporadic SCA.
Results showed a 40% reduction in SARA total score and 10–20%
average improvement in gait parameters. Patients improved the
best after the third course and continued to improve until 28
days after the last infusion. Patients improvements declined by
56 days after the last infusion (Zesiewicz et al., 2014).
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Calcium-mediated neurodegeneration has attracted
considerable attention in the past couple of decades (Jimenez-
Jimenez et al., 1996; Wojda et al., 2008); therefore a discussion
on calcium-focused treatments for SCA 1 is warranted. Studies
have shown SCA 1 model exhibiting down-regulation of proteins
involved in PC calcium homeostasis, particularly Calbindin
and Paravalbumin (Vig et al., 2000, 2001). Dantrolene has been
tested on SCA 2 and SCA 3. Liu et al. found that mutant ataxin-2
facilitated inositol phosphate-induced Ca2+ release in cultured
PC of a transgenic SCA 2 mouse model. Dantrolene blocked the
Ca2+ release in vitro and, when given orally to mutant transgenic
mice from 2 to 11 months old substantially reduced expression
of SCA 2 (Liu et al., 2009). Chen et al. demonstrated that mutant
ATXN3 associated with type 1 inositol 1,4,5-triphosphate
receptor, an intracellular calcium release channel. They went
on to demonstrate oral administration of dantrolene to SCA 3
transgenic mice stopped neuronal cell loss and improved motor
performance, and stated dantrolene should be considered as
a possible therapeutic for SCA 3 patients (Chen et al., 2008).
Dantrolene should also be considered as a potential therapeutic
for SCA 1.
HURDLES
At first glance, gene and cell therapies for SCA 1 seem to be
straightforward. Gene therapy approaches involve the delivery
of a transgene that can replace, silence, or inhibit the defective
gene. Alternatively, the delivery of stem cells might replace the
dying cell pool or provide a protective environment that would
prevent these cells from dying. But in practice the process is more
complex and a certain number of variables need to be controlled
and optimized.
First, a route of delivery needs to be chosen. While
peripheral administration (such as intravenous, intramuscular,
or intranasal) sounds more appealing and less invasive, it raises
several barriers. Higher dosages are needed to reach the same
effect compared to a central delivery approach. Transduction of
non-CNS tissues carries the risk of off-target effects. Finally, most
gene therapy vectors lack the ability to cross the blood brain
barrier.
Direct delivery to the CNS can be achieved via
intraparenchymal injections to brain and spinal cord structures
or via injections into the CSF (intrathecal or intraventricular).
While these approaches offers the benefit of being more targeted,
for SCA 1 a specific brain region may need to be chosen, such as
deep cerebellar nuclei or cerebellar hemispheres. Additionally,
surgical techniques need to be developed and optimized to be
more reproducible and accurate. While these methods are more
invasive, direct delivery of viral vectors and stem cells into the
CNS have proven safe and effective (Marks et al., 2010; Gutierrez
et al., 2015).
Concerning stem cells, it is also very important to determine
the factors behind successful grafts. Many studies do not
characterize graft survival or the factors that allow these cells
to slow the rate of disease progression. The description of graft
characteristics and features would help predict the outcomes and
help choose the optimal cell type for type of injection and brain
region receiving the injection.
CONCLUSION
A wide variety of therapies for SCA 1 are being investigated to
preserve PCs and slow disease onset and progression. While stem
cell therapies are the ones that have currently reached the clinical
trial stage, recent progress in gene and protein delivery appear
to be equally promising for SCA 1 treatment. Mouse models,
particularly the 154Q/2Q mouse, provide a valuable model of
the disease. However, the mechanism of action of polyQ-ATXN1
is not entirely understood and further research is needed to
understand the disease process. Conceptually speaking, RNAi
therapies, be they siRNA, shRNA, or miRNA-based, seem to be
themost promising, since they deal directly with the root cause of
the disease. All three RNAi options have been efficacious in SCA 1
models as well as models for other polyQ diseases. However,
transducing a large majority of neurons throughout the brain
remains a hurdle for gene therapy. Clinical trials will be necessary
to determine which therapies or combinations of therapies will
result in the best outcomes for patients.
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